The EMA's human medicines committee recommended approval of Lilly's once-daily orforglipron pill on Oct. 15, as Viking started Phase 3 trials of oral VK2735 and Nature Medicine reported a Phase 3 trial of safiglipron.
An observational study in Nature Medicine tracked 8,127 women prescribed GLP-1 drugs, almost all tirzepatide, through a remote UK service. Mean weight loss was 16.1 kg at six months; there was no comparison group.
WHO's first guidelines on child and adolescent obesity put structured diet, activity and behavior programs first, and rule out drugs, surgery and devices for children under 10.
